NCT07714551 clinical trial report covering Zanzalintinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07712926 clinical trial report covering Tetravalent dengue virus vaccine(Instituto Butantan), Phase 3, endpoints, sponsor, geography, readout timing and de

NCT07714616 clinical trial report covering Cyproterone Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

SillaJen 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Genexine 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Ractigen Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sirnaomics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Suzhou Ribo Life Science 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Stemirna Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Immorna Biotherapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Shanghai Cell Therapy Group 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Oricell Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.